Regulatory News
Monday, November 7, 2016
BRIEF-Coherus Biosciences receives decision denying institution of '166 IPR related to AbbVie's Humira formulation
* Coherus biosciences receives decision denying institution
of the '166 IPR related to AbbVie's Humira formulation
Read more
No comments:
Post a Comment
Newer Post
Older Post
Home
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment